Clinical Trial

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-02
Trial Details
NCT Number NCT07511816
Lead Sponsor Eli Lilly and Company
Conditions Acute Pain, Molar, Molar, Third, Surgery, Oral
Enrollment 212 participants
Start Date 2026-04-01
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-01